Takeda Pharmaceutical Co.’s experimental dengue vaccine was highly effective at preventing the mosquito-borne disease in a late stage study, but TAK-003 failed to protect against one type of the virus in people with no prior exposure to dengue.
Prior infection with dengue, a mosquito-borne disease that infects nearly 400 million people a year, could reduce the risk of contracting Zika nearly by half, U.S. and Brazilian researchers reported.
Takeda Pharmaceutical’s experimental dengue vaccine appears to be safe and effective at preventing all four types of the mosquito-borne disease, meeting the main goal of a late-stage clinical trial.
A case of yellow fever – an acute and contagious mosquito-borne viral disease – was reported in a man in the Netherlands who recently traveled to Gambia and Senegal, the World Health Organization said.
Japan’s Takeda Pharmaceutical Co. Ltd. said on Monday the U.S. Food and Drug Administration granted ‘fast track’ status to its vaccine for the mosquito-borne Zika virus.
Sanofi management expressed confidence that the company’s pipeline of new products will support long-term growth.
The Philippines will seek the return of 3 billion pesos ($59 million) it paid French drugmaker Sanofi for a dengue vaccine used to immunize hundreds of thousands of children that Sanofi has said could worsen the disease in some cases.
The Philippines has ordered French drugmaker Sanofi to stop the sale, distribution and marketing of its Dengvaxia dengue vaccine in the country.
A Zika vaccine Sanofi SA dropped during September 2017 under political pressure over pricing produced strong responses in more than 90 percent of those taking part in an early-stage clinical trial, U.S. researchers reported.
The Philippines ordered a probe on Monday into the immunization of more than 730,000 children with a vaccine for dengue that has been suspended following an announcement by the French drug company Sanofi that it could worsen the disease in some cases.